Testing Asset Pricing Models: Restrictions, Factors, and Model Choice
Summary
The document distinguishes testing whether a pricing model’s restrictions hold from comparing a larger model with a restricted version. It uses the CAPM and an expanded cross-sectional return regression to show how intercepts and coefficients on additional risk measures can indicate departures from the CAPM. Because betas and idiosyncratic risk are estimated first, the example uses a two-stage procedure and relies on statistical inference about the resulting coefficients.
The discussion of a three-factor model adds a key distinction: a factor’s average return alone does not determine whether it can be removed, since other factor exposures may change when the model is refit. A factor may improve explanatory power while affecting pricing validity, represented by the intercept. The answers caution that estimates are noisy and that model choice depends on the task, such as explaining returns, improving precision, or evaluating pricing restrictions. They mention BIC as a consistent criterion for choosing among submodels, while noting that the cited advice does not fully specify inference or selection procedures.
Key ideas
- Testing a pricing model asks whether its implied coefficient restrictions are consistent with the data.
- Comparing a model with a restricted version requires accounting for how all estimated exposures change when a factor is removed.
- A factor can improve explanatory power while changing the pricing model’s intercept and validity.
- The preferred comparison depends on whether the goal is return explanation, parameter precision, or asset pricing validity.
- Statistical noise makes coefficient estimates differ from theoretical values, so model tests need an explicit uncertainty framework.
Tags
Full text
# Testing as in Fama & MacBeth vs. comparing models as in Cochrane's lecture notes
# Testing as in Fama & MacBeth vs. comparing models as in Cochrane's lecture notes
#### Testing a model against its extension as in Fama & MacBeth (1973)
Fama & MacBeth (1973) tested the CAPM against an alternative that the dependence between the expected excess return $E(r_{i,t}^∗)$ and the relative systematic risk $\beta_𝑖$ is nonlinear (namely, quadratic) and that the idiosyncratic risk $\sigma_i$ commands nonzero expected return. The corresponding cross-sectional regression is (using different notation from the original, but keeping the equation number for reference) $$ r_{i,t}^∗ = \lambda_0 + \lambda_1 \beta_i + \lambda_2 \beta_i^2 + \lambda_3 \sigma_i + u_{i,t}. \tag{7} $$ Since $\beta_i$ and $\sigma_i$ are not observed, a two-stage procedure is used where $\beta_i$ and $\sigma_i$ are first estimated from time-series regressions and then their fitted values are used in cross-sectional regressions (one for every time period) of the type specified above. The CAPM implies $\lambda_0=\lambda_2=\lambda_3=0$ and $\lambda_1>0$.
Let us simplify and drop the term $\lambda_2 \beta_i^2$ to obtain $$ r_{i,t}^∗ = \lambda_0 + \lambda_1 \beta_i + \lambda_3 \sigma_i + u_{i,t}. \tag{*} $$ The CAPM implies $\lambda_0=\lambda_3=0$ and $\lambda_1>0$. This can be used for testing the model. If the estimated values are statistically distinguishable from what the model implies, we have evidence against the model.
#### Comparing a model against a submodel as suggested by Cochrane
We could also consider $(*)$ to be a competitor of the CAPM and ask, which one is the better model? Here is what John Cochrane writes about testing one model versus another (section 14.6 in his lectures notes for the course Business 35150 Advanced Investments, p. 239-240):
> Example. FF3F. $$ E(R^{ei}) = \alpha_i + b_i\lambda_{rmrf} + h_i\lambda_{hml} + s_i\lambda_{smb} \tag{i} $$ Do we really need the size factor? Or can we write $$ E(R^{ei}) = \alpha_i + b_i\lambda_{rmrf} + h_i\lambda_{hml} \tag{ii} $$ and do as well? ($\alpha$ will rise, but will they rise “much”?)
> A common misconception: Measure $\lambda_{smb} = E(smb)$. If $\lambda_{smb} = 0$ (and “small”) we can drop it. Why is this wrong? Because if you drop $smb$ from the regression, $b_i$ and $h_i$ also change!
> <...>
> Solution: (a) “ First run a regression of $smb_t$ on $rmrf_t$ and $hml_t$ and take the residual, $$ smb_t = \alpha_{smb} + b_s rmrf_t + h_s hml_t + \varepsilon_t \tag{iii} $$ Now, we can drop $smb$ from the three factor model if and only $\alpha_{smb}$ is zero. Intuitively, if the other assets are enough to price $smb$, then they are enough to price anything that $smb$ prices.
#### Contradiction?
How do I reconcile the Fama & MacBeth approach with Cochrane's advice? Cochrane's second point is directly against what Fama & MacBeth suggest doing. Is there a contradiction? Fama & MacBeth are looking for violations of the CAPM, while Cochrane shows us how to compare alternative models. These are not entirely the same thing, but they seem to be closely related, especially since both deal with a model and a submodel (a restricted model). If I find that model B is better than model A, does it not suggest that A is violated?
#### References
- Cochrane, J. H. (2014). Week 5 Empirical methods notes. Business 35150 Advanced Investments, 225-247.
- Fama, E. F., & MacBeth, J. D. (1973). Risk, return, and equilibrium: Empirical tests. Journal of Political Economy, 81(3), 607-636.
## Answer by Brian B (score 1)
https://quant.stackexchange.com/a/77439
Both Fama & Macbeth and Cochrane are playing a bit loose, statistically, in their recommended procedures here. First off, numerical noise more or less guarantees that you will measure e.g. $\lambda_0 \neq 0$ and $\alpha_{smb} \neq 0$. Without qualifying what error bars they truly mean to employ in these criteria, the question of whether they contradict is mathematically undecideable.
I will say that Cochrane's second point is no contradiction to F&M -- here Cochrane is simply noting that a univariate regression is no way to learn the model parameters.
For readers wondering what approach should be taken to distinguish between a model and a submodel, I suggest the 4-page paper Estimating the Dimension of a Model by Schwarz, in which we see that the Bayesian Information Criterion (BIC) is preferable to Akaike Information Criterion (AIC) when choosing among submodels, because the latter is not consistent.
By not recommending BIC in 2014, Cochrane is being a little sloppy. (I can't really fault a 1973 paper for lacking AIC or BIC).
## Answer by Richard Hardy (score 1)
https://quant.stackexchange.com/a/77512
In this answer, the terms intercept, slope coefficient and $R^2$ refer to the true parameter values corresponding to the regression model in population. They do not refer to estimates unless explicitly specified.
#### Comparing a model against a submodel as suggested by Cochrane
The intercept in each of the equations $(7)$, $(*)$, $(\text{i})$ and $(\text{ii})$ is informative of the validity of the corresponding asset pricing model. The model implies the intercept must be zero. If the intercept is nonzero, the model is invalid (as in at odds with the data). Adding or removing a (potential) pricing factor will affect the validity of the model unless the intercept is unchanged. The intercept in $(\text{i})$ is unchanged only if the intercept in $(\text{iii})$ is zero. This is why Cochrane recommends testing whether the intercept in $(\text{iii})$ is zero as a criterion of adding or removing a (potential) pricing factor. He cares about the validity of the model, thus the choice.
#### Testing a model against its extension as in Fama & MacBeth (1973)
The slope coefficient (such as $s_i$ in $(\text{i})$) corresponding to an asset's sensitivity to a (potential) pricing factor is informative of the model's explanatory power. If the asset returns vary with their factor sensitivity* conditional on sensitivities to the other factors in the model, the slope coefficient will be nonzero (and the $R^2$ will be greater in a model containing the factor than in one without it). If we are interested in whether the presence of a (potential) pricing factor adds some explanatory power to the model, we can test whether the corresponding slope coefficient equals zero. We should keep in mind that having this additional explanatory power might come at an expense of making the pricing model invalid (or bringing it further away from validity) through its impact on the intercept. However, it is also possible that presence of the factor not only improves the model's explanatory power but also makes the model valid (or brings it closer to validity) at the same time.
#### When to use which approach
As Cochrane notes in points 5. and 6. on p. 240-241 of the linked lecture note, having more explanatory power is beneficial, as that makes the regression errors smaller and thus measurements better (estimates of the parameters more precise, hypothesis tests more powerful). He concludes that inclusion of a factor depends on the intended use of the model. E.g. if you want to arbitrage, including a factor with high additional explanatory power is helpful. Meanwhile, if you want a valid (or closer to valid) asset pricing model, pay attention to the effect that a factor's inclusion or exclusion has on the intercept.
*Except for the case of $\sigma_i$ in $(7)$ and $(*)$; there, $\sigma_i$ is an individual characteristic rather than factor sensitivity.Shown in full with attribution under the source's licence. Licence: CC BY-SA 4.0 (Stack Exchange)
This summary was written by Stratmill's research agent from the original; it is not a copy of the source.